Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXFORGE HCT vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EXFORGE HCT is a combination of amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and water by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension: treatment of hypertension to lower blood pressure (FDA-approved)
Hypertension
One tablet orally once daily. Initial dose based on previous antihypertensive therapy; maximum dose is one tablet of 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide per day.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Valsartan: 6 hours (terminal). Amlodipine: 30-50 hours (terminal), permits once-daily dosing. Hydrochlorothiazide: 6-15 hours (terminal).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Amlodipine is extensively metabolized in the liver via CYP3A4; valsartan is minimally metabolized (about 20%) via CYP2C9; hydrochlorothiazide is not metabolized and is excreted unchanged.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Valsartan: 13% excreted unchanged in urine, 83% in feces via biliary secretion. Amlodipine: 10% excreted unchanged in urine, 60% as metabolites in urine, 20-25% in feces. Hydrochlorothiazide: ≥95% excreted unchanged in urine.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Valsartan: 94-97% (primarily albumin). Amlodipine: ~93% (albumin). Hydrochlorothiazide: 40-68% (albumin).
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Valsartan: 17 L (0.24 L/kg); indicates limited extravascular distribution. Amlodipine: 21 L/kg; extensive tissue distribution. Hydrochlorothiazide: 3-15 L (0.05-0.2 L/kg); distributes into extracellular fluid.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: Valsartan 25% (wide range 10-35%), amlodipine 64-90%, hydrochlorothiazide 65-75%.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated in anuria. For GFR 30-60 m L/min: no dose adjustment needed, but monitor serum potassium and creatinine. For GFR <30 m L/min: not recommended due to limited data.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh Class A: no adjustment; Class B: maximum dose 5 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide; Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
Not established; avoid use in children.
Initiate at the lowest available dose (5 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide) and titrate slowly; monitor renal function, electrolytes, and blood pressure due to increased risk of hypotension and electrolyte imbalance.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
WARNING: FETAL TOXICITY. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
None
Fetal toxicity: avoid use in pregnancy; discontinue if pregnancy occurs.,Hypotension: symptomatic hypotension may occur, especially in volume-depleted patients.,Electrolyte and metabolic effects: hydrochlorothiazide may cause hypokalemia, hyponatremia, hypercalcemia, hypomagnesemia, and hyperglycemia.,Renal function deterioration: monitor renal function; may cause acute renal failure.,Hepatic impairment: use caution in patients with severe hepatic impairment.,Angioedema: reported with valsartan; monitor for swelling of face, lips, throat.,Avoid concomitant use with aliskiren in patients with diabetes or renal impairment.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to any component.,Anuria (due to hydrochlorothiazide).,Concomitant use with aliskiren in patients with diabetes mellitus.,Severe renal impairment (e GFR <30 m L/min/1.73 m²).,Pregnancy (second and third trimesters).,Hereditary fructose intolerance (due to sorbitol excipient in some formulations).
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes) and salt substitutes with potassium unless instructed otherwise. Grapefruit juice may increase amlodipine levels; limit consumption. Alcohol may enhance hypotensive effects. Maintain adequate fluid intake to prevent dehydration.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Drugs acting on renin-angiotensin system (ARB/ACEi component: valsartan) associated with increased risk of fetal renal dysfunction, oligohydramnios, skull ossification defects, and fetal death if exposed during first trimester. However, major teratogenic risk is primarily second and third trimester. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Second and third trimester: Valsartan exposure is associated with oligohydramnios, fetal renal failure, skull hypoplasia, anuria, and death. HCTZ can cause fetal electrolyte imbalances, jaundice, and thrombocytopenia. Avoid use in pregnancy, especially second and third trimesters.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Valsartan: Not known if excreted in human milk; due to potential for adverse effects on infant kidney function, caution advised. Hydrochlorothiazide: Excreted in breast milk in small amounts; M/P ratio approximately 0.6. May suppress lactation. Use only if clearly needed, monitoring infant for electrolyte disturbances and dehydration.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Not recommended for use in pregnancy. If unavoidable, use lowest effective dose; however, pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may require dose adjustments, but safety data insufficient. Generally, avoid use.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Exforge HCT is a triple combination of amlodipine, valsartan, and hydrochlorothiazide. It is indicated for hypertension not adequately controlled on dual therapy. Monitor serum potassium, especially in patients with renal impairment or on NSAIDs. Avoid use in pregnancy due to direct renin-angiotensin system effects. Titrate doses based on blood pressure response. Common side effects include peripheral edema (amlodipine), dizziness, and electrolyte disturbances (HCTZ).
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed, usually once daily with or without food.,Do not stop taking this medication without consulting your doctor.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or low blood pressure (dizziness, fainting).,Avoid potassium supplements or salt substitutes containing potassium unless advised by your doctor.,Limit alcohol intake as it may increase blood pressure or cause dizziness.,If pregnant or planning pregnancy, inform your doctor immediately as this drug can harm an unborn baby.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Stay hydrated to prevent dehydration from hydrochlorothiazide, especially if you sweat heavily or have diarrhea/vomiting.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXFORGE HCT vs ALDORIL 25, answered by our medical review team.
EXFORGE HCT is a Antihypertensive that works by EXFORGE HCT is a combination of amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and water by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXFORGE HCT and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXFORGE HCT is: One tablet orally once daily. Initial dose based on previous antihypertensive therapy; maximum dose is one tablet of 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide per day.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXFORGE HCT and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXFORGE HCT is classified as Category C. First trimester: Drugs acting on renin-angiotensin system (ARB/ACEi component: valsartan) associated with increased risk of fetal renal dysfunction, oligohydramnios, skull ossifica. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.